Molecular Target Synopsis
Domains and Structures
Drugs and Clinical Candidates
Ligand Efficiency Plot
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
Germline Genetics

PRE2 (P30656) - Overview - Molecular Target Synopsis


PRE2, Proteasome subunit beta type-5
Enzyme Classification
UniProt P30656

Also Known as PSB5_YEAST, PRE2, DOA3, PRG1

The proteasome degrades poly-ubiquitinated proteins in the cytoplasm and in the nucleus. It is essential for the regulated turnover of proteins and for the removal of misfolded proteins. The proteasome is a multicatalytic proteinase complex that is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. It has an ATP-dependent proteolytic activity. This unit is responsible of the chymotrypsin-like activity of the proteasome and is one of the principal target of the proteasome inhibitor bortezomib., This subunit is necessary for chymotryptic activity and degradation of ubiquitinated proteins. The 26S proteasome consists of a 20S proteasome core and two 19S regulatory subunits. The 20S proteasome core is composed of 28 subunits that are arranged in four stacked rings, resulting in a barrel-shaped structure. The two end rings are each formed by seven alpha subunits, and the two central rings are each formed by seven beta subunits. The catalytic chamber with the active sites is on the inside of the barrel.

Inspect Structure
See all 3D Structures for PRE2

Isoforms / Transcripts (Protein Coding)

Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform

Sub-cellular localization

UniProt: PRE2 is active in the following subcellular-locations: cytoplasm, nucleus.
GO terms: PRE2 is active in the following subcellular-locations: cytoplasm, cytosol, endoplasmic reticulum membrane, nucleus, proteasome core complex, proteasome core complex, proteasome storage granule.

GO terms

Gene Copy Number Variation

In COSMIC - Cell Lines Project PRE2 has gain in 0 cell-lines, loss in 0 cell-lines and no signal in 0 cell-lines. (see details)

3D Structures

For PRE2 there are:
288 structures (570 chains) solved
213 are solved in complex with at least one small molecule ligand
20 are solved with an approved drug

PRE2 is solved in complex with the approved drug(s):

BO2/BORTEZOMIB (2F16_K, 2F16_Y, 3MG0_K, 3MG0_Y, 4QVL_K, 4QVL_Y, 4QVM_K, 4QVM_Y, 4QVN_K, 4QVN_Y, 4QVP_K, 4QVP_Y, 4QVQ_K, 4QVQ_Y, 4QVV_K, 4QVV_Y, 4QVW_K, 4QVW_Y, 4QVY_K, 4QVY_Y, 4QW0_K, 4QW0_Y, 4QW1_K, 4QW1_Y, 4QW3_K, 4QW3_Y, 4QWU_K, 4QWU_Y, 5BXN_K, 5BXN_Y, 5D0X_K, 5D0X_Y, 5L5F_K, 5L5F_Y, 5L5Z_K, 5L5Z_Y, 5L66_K, 5L66_Y, 6HWD_K, 6HWD_Y).

(see details)
Molecular Target 3D Synopsis

Screening and Chemistry

PRE2 has been screened with 43 compounds (43 bioactivities). (see details)